Cargando…

Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor

Plerixafor is widely used as up-front treatment with G-CSF to enhance peripheral blood hematopoietic stem cell output in patients failing previous mobilizations. Less frequently, plerixafor is used to rescue an unsatisfactory mobilization following chemotherapy (CT) and G-CSF. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentini, Caterina Giovanna, Pellegrino, Claudio, Putzulu, Rossana, Bonanni, Matteo, Massini, Giuseppina, Orlando, Nicoletta, Forni, Franca, Bianchi, Maria, Piccirillo, Nicola, Teofili, Luciana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866585/
https://www.ncbi.nlm.nih.gov/pubmed/36675546
http://dx.doi.org/10.3390/jcm12020618
_version_ 1784876128197935104
author Valentini, Caterina Giovanna
Pellegrino, Claudio
Putzulu, Rossana
Bonanni, Matteo
Massini, Giuseppina
Orlando, Nicoletta
Forni, Franca
Bianchi, Maria
Piccirillo, Nicola
Teofili, Luciana
author_facet Valentini, Caterina Giovanna
Pellegrino, Claudio
Putzulu, Rossana
Bonanni, Matteo
Massini, Giuseppina
Orlando, Nicoletta
Forni, Franca
Bianchi, Maria
Piccirillo, Nicola
Teofili, Luciana
author_sort Valentini, Caterina Giovanna
collection PubMed
description Plerixafor is widely used as up-front treatment with G-CSF to enhance peripheral blood hematopoietic stem cell output in patients failing previous mobilizations. Less frequently, plerixafor is used to rescue an unsatisfactory mobilization following chemotherapy (CT) and G-CSF. This study investigates if pre-collection factors affect the CD34+ cell harvest in chemotherapy and G-CSF mobilizations rescued by plerixafor. Clinical and hematological data relative to patients, mobilization, and apheresis products were retrospectively examined. The outcome was completing a target cell dose ≥ 2 × 10(6) CD34+ cells/kg at first apheresis. The effect exerted on the outcome by patient- and disease-related factors was investigated by univariate and multivariate logistic regression analysis. The analysis included data from 42 patients affected by hematological (39 patients) and non-hematological malignancies (three patients). Twenty-nine patients (69%) attained the target cell dose at first apheresis. Twelve out of the remaining 13 patients received an additional plerixafor administration, and all accomplished the transplant dose at a second apheresis procedure. Day -1 CD34+ PB count (OR1.46, 95% CI 1.1–1.9, p = 0.008) and platelet count (OR1.0, 95% CI 1.0–1.0, p = 0.033) predicted the achievement of the target dose at first apheresis, independently of pre-mobilization CT, radiation therapy, and disease status at mobilization. At ROC curve analysis, the best cut-off value predicting the successful collection at first apheresis was 7.5/µL for Day -1 CD34+ cell count (AUC 0.830, 0.69 sensitivity, and 0.92 specificity) and 75 × 10(9)/L for Day -1 platelet count (AUC = 0.736, 0.65 sensitivity and 0.85 specificity). In conclusion, on-demand plerixafor rescue allows a successful stem cell collection, irrespectively of disease type and status, prior CT lines, and radiation exposure. Pre-apheresis CD34+ cells and platelet count predict the need for one or two aphereses.
format Online
Article
Text
id pubmed-9866585
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98665852023-01-22 Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor Valentini, Caterina Giovanna Pellegrino, Claudio Putzulu, Rossana Bonanni, Matteo Massini, Giuseppina Orlando, Nicoletta Forni, Franca Bianchi, Maria Piccirillo, Nicola Teofili, Luciana J Clin Med Article Plerixafor is widely used as up-front treatment with G-CSF to enhance peripheral blood hematopoietic stem cell output in patients failing previous mobilizations. Less frequently, plerixafor is used to rescue an unsatisfactory mobilization following chemotherapy (CT) and G-CSF. This study investigates if pre-collection factors affect the CD34+ cell harvest in chemotherapy and G-CSF mobilizations rescued by plerixafor. Clinical and hematological data relative to patients, mobilization, and apheresis products were retrospectively examined. The outcome was completing a target cell dose ≥ 2 × 10(6) CD34+ cells/kg at first apheresis. The effect exerted on the outcome by patient- and disease-related factors was investigated by univariate and multivariate logistic regression analysis. The analysis included data from 42 patients affected by hematological (39 patients) and non-hematological malignancies (three patients). Twenty-nine patients (69%) attained the target cell dose at first apheresis. Twelve out of the remaining 13 patients received an additional plerixafor administration, and all accomplished the transplant dose at a second apheresis procedure. Day -1 CD34+ PB count (OR1.46, 95% CI 1.1–1.9, p = 0.008) and platelet count (OR1.0, 95% CI 1.0–1.0, p = 0.033) predicted the achievement of the target dose at first apheresis, independently of pre-mobilization CT, radiation therapy, and disease status at mobilization. At ROC curve analysis, the best cut-off value predicting the successful collection at first apheresis was 7.5/µL for Day -1 CD34+ cell count (AUC 0.830, 0.69 sensitivity, and 0.92 specificity) and 75 × 10(9)/L for Day -1 platelet count (AUC = 0.736, 0.65 sensitivity and 0.85 specificity). In conclusion, on-demand plerixafor rescue allows a successful stem cell collection, irrespectively of disease type and status, prior CT lines, and radiation exposure. Pre-apheresis CD34+ cells and platelet count predict the need for one or two aphereses. MDPI 2023-01-12 /pmc/articles/PMC9866585/ /pubmed/36675546 http://dx.doi.org/10.3390/jcm12020618 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Valentini, Caterina Giovanna
Pellegrino, Claudio
Putzulu, Rossana
Bonanni, Matteo
Massini, Giuseppina
Orlando, Nicoletta
Forni, Franca
Bianchi, Maria
Piccirillo, Nicola
Teofili, Luciana
Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title_full Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title_fullStr Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title_full_unstemmed Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title_short Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
title_sort day -1 cd34+ cells and platelet count predict the number of apheresis in poor-mobilizer patients rescued by plerixafor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866585/
https://www.ncbi.nlm.nih.gov/pubmed/36675546
http://dx.doi.org/10.3390/jcm12020618
work_keys_str_mv AT valentinicaterinagiovanna day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT pellegrinoclaudio day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT putzulurossana day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT bonannimatteo day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT massinigiuseppina day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT orlandonicoletta day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT fornifranca day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT bianchimaria day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT piccirillonicola day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor
AT teofililuciana day1cd34cellsandplateletcountpredictthenumberofapheresisinpoormobilizerpatientsrescuedbyplerixafor